Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Payne, S. R.
Right arrow Articles by Kemp, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Payne, S. R.
Right arrow Articles by Kemp, C. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

p27 Kip1 (Cdkn1b)-Deficient Mice Are Susceptible to Chemical Carcinogenesis and May Be a Useful Model for Carcinogen Screening

Shannon R. Payne

Fred Hutchinson Cancer Research Center C1-015, PO Box 19024, 1100 Fairview Ave N., Seattle Washington, 90109-1024

Christopher J. Kemp

Fred Hutchinson Cancer Research Center C1-015, PO Box 19024, 1100 Fairview Ave N., Seattle Washington, 90109-1024, cjkemp@ fhcrc.org

The two-year rodent bioassay is one of several tests that are widely used by governmental regulatory agencies as well as pharmaceutical and chemical companies to determine the carcinogenic potential of chemicals or environmental agents where human exposure is anticipated. That this assay has remained relatively unchanged for the last 25 years is a testament to the power of this approach to identify carcinogens and thus to minimize human exposure. However, there has long been controversy over the specificity and relevance of the rodent bioassay as well as its high cost in terms of time, expense, and numbers of mice. Much discussion has been generated in recent years over how to improve the 2-year rodent bioassay for more accurate and faster detection of potential human carcinogens. Here, we argue that the use of p27Kip1 (Cdkn1b) knockout mouse for carcinogen screening may solve several shortcomings inherent in the conventional bioassay while preserving its best quality, that is, protecting public health by providing reliable in vivo information on the potential of chemicals to cause cancer.

Key Words: p27 • Kip1 • Cdkn1b • haploinsufficient • tumor suppressor • carcinogen.

References

  • Blanchard KT, Ball DJ, Holden HE, Furst SM, Stoltz JH, Stoll RE (1998). Dermal carcinogenicity in transgenic mice: Relative responsiveness of male and female hemizygous and homozygous Tg.AC mice to 12-O-tetradecanoylphorbol 13-acetate (TPA) and benzene. Toxicol Pathol 26: 541—547.[Abstract/Free Full Text]
  • Cannon RE, Spalding JW, Trempus CS, Szczesniak CJ, Virgil KM, Humble MC, Tennant RW (1997). Kinetics of wound-induced v-Ha-ras transgene expression and papilloma development in transgenic Tg.AC mice. Mol Carcinog 20: 108—114.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cannon RE, Spalding JW, Virgil KM, Faircloth RS, Humble MC, Lacks GD, Tennant RW (1998). Induction of transgene expression in Tg.AC(v-Ha-ras) transgenic mice concomitant with DNA hypomethylation. Mol Carcinog 21: 244—250.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Catzavelos C., Bhattacharya N., Ung YC, Wilson JA, Roncari L., Sandhu C., Shaw P., Yeger H., Morava-Protzner I., Kapusta L., Franssen E., Pritchard KI, Slingerland JM (1997). Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer [see comments]. Nature Medicine 3: 227—230.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cheng T., Rodrigues N., Dombkowski D., Stier S., Scadden DT (2000). Stem cell repopulation efficiency but not pool size is governed by p27(kip1). Nat Med 6: 1235—1240.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Chiarle R., Budel LM, Skolnik J., Frizzera G., Chilosi M., Corato A., Pizzolo G., Magidson J., Montagnoli A., Pagano M., Maes B., Wolf-Peeters C., Inghirami G. (2000). Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 95: 619—626.[Abstract/Free Full Text]
  • Ciaparrone M., Yamamoto H., Yao Y., Sgambato A., Cattoretti G., Tomita N., Monden T., Rotterdam H., Weinstein IB (1998). Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. Cancer Res 58: 114— 122.
  • Cohen SM (2001). Alternative models for carcinogenicity testing: Weight of evidence evaluations across models. Toxicol Pathol 29(Suppl): 183—190.[Abstract/Free Full Text]
  • Cote RJ, Shi Y., Groshen S., Feng AC, Cordon-Cardo C., Skinner D., Lieskovosky G. (1998). Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 90: 916—920.[Abstract/Free Full Text]
  • Del Pizzo JJ, Borkowski A., Jacobs SC, Kyprianou N. (1999). Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol 155: 1129—1136.[Abstract/Free Full Text]
  • Delker DA, Yano BL, Gollapudi BB (1999). V-Ha-ras gene expression in liver and kidney of transgenic Tg.AC mice following chemically induced tissue injury. Toxicol Sci 50: 90—97.[Abstract/Free Full Text]
  • Deschenes C., Vezina A., Beaulieu JF, Rivard N. (2001). Role of p27(Kip1) in human intestinal cell differentiation. Gastroenterology 120: 423— 438.
  • Di Cristofano A., De Acetis M., Koff A., Cordon-Cardo C., Pandolfi PP (2001). Pten and p27Kip1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 27: 222—224.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Erlanson M., Portin C., Linderholm B., Lindh J., Roos G., Landberg G. (1998). Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. Blood 92: 770—777.[Abstract/Free Full Text]
  • Esposito V., Baldi A., De Luca A., Groger AM, Loda M., Giordano GG, Caputi M., Baldi F., Pagano M., Giordano A. (1997). Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57: 3381—3385.[Abstract/Free Full Text]
  • Farnsworth CL, Marshall MS, Gibbs JB, Stacey DW, Feig LA (1991). Preferential inhibition of the oncogenic form of rasH by mutations in the GAP binding/"effector" domain. Cell 64: 625—633.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fero ML, Randel E., Gurley KE, Roberts JM, Kemp CJ ( 1998). The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 396: 177—180.[CrossRef][Medline] [Order article via Infotrieve]
  • Fero ML, Rivkin M., Tasch M., Porter P., Carow CE, Firpo E., Polyak K., Tsai LH, Broudy V., Perlmutter RM, Kaushansky K., Roberts JM (1996). A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27-deficient mice. Cell 85: 733—744.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Finch GL, March TH, Hahn FF, Barr EB, Belinsky SA, Hoover MD, Lechner JF, Nikula KJ, Hobbs CH (1998). Carcinogenic responses of transgenic heterozygous p53 knockout mice to inhaled 239PuO2 or metallic beryllium. Toxicol Pathol 26: 484—491.[Abstract/Free Full Text]
  • Franklin DS, Godfrey VL, Lee H., Kovalev GI, Schoonhoven R., Chen-Kiang S., Su L., Xiong Y. (1998). CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 12: 2899—2911.[Abstract/Free Full Text]
  • Fredersdorf S., Burns J., Milne AM, Packham G., Fallis L., Gillett CE, Royds JA, Peston D., Hall PA, Hanby AM, Barnes DM, Shousha, S., O'Hare MJ, Lu X. (1997). High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 94: 6380—6385.[Abstract/Free Full Text]
  • French J., Storer RD, Donehower LA (2001). The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens. Toxicol Pathol 29(Suppl): 24—29.[Abstract/Free Full Text]
  • Gulezian D., Jacobson-Kram D., McCullough CB, Olson H., Recio L., Robinson D., Storer R., Tennant R., Ward JM, Neumann DA (2000). Use of transgenic animals for carcinogenicity testing: Considerations and implications for risk assessment. Toxicol Pathol 28: 482—499.[Abstract/Free Full Text]
  • Gunther K., Jung A., Volker U., Meyer M., Brabletz T., Matzel KE, Reymond MA, Kirchner T., Hohenberger W. (2000). p27(kip1) expression in rectal cancer correlates with disease-free survival. J Surg Res 92: 78— 84.
  • Hengst L., Dulic V., Slingerland JM, Lees E., Reed SI ( 1994). A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci USA 91: 5291—5295.[Abstract/Free Full Text]
  • Holden HE, Stoll RE, Spalding JW, Tennant RW (1998). Hemizygous Tg.AC transgenic mouse as a potential alternative to the two-year mouse carcinogenicity bioassay: Evaluation of husbandry and housing factors. J Appl Toxicol 18: 19—24.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Honchel R., Rosenzweig BA, Thompson KL, Blanchard KT, Furst SM, Stoll RE, Sistare FD (2001). Loss of palindromic symmetry in Tg.AC mice with a nonresponder phenotype. Mol Carcinog 30: 99—110.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kim DH, Lee HI, Nam ES, Shin HS, Sohn JH, Park CH, Yoon DS, Song SY, Park YE ( 2000). Reduced expression of the cell-cycle inhibitor p27Kip1 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 36: 245—251.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Korkolopoulou P., Christodoulou P., Konstantinidou AE, Thomas-Tsagli E., Kapralos P., Davaris P. (2000). Cell cycle regulators in bladder cancer: A multivariate survival study with emphasis on p27Kip1. Hum Pathol 31: 751—760.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kwon OJ, Kang HS, Suh JS, Chang MS, Jang JJ, Chung JK (1999). The loss of p27 protein has an independent prognostic significance in gastric cancer. Anticancer Res 19: 4215—4220.[Web of Science][Medline] [Order article via Infotrieve]
  • Leder A., Kuo A., Cardiff RD, Sinn E., Leder P. (1990). v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: Effects of phorbol esters and retinoic acid. Proc Natl Acad Sci USA 87: 9178—9182.[Abstract/Free Full Text]
  • Levkau B., Koyama H., Raines EW, Clurman BE, Herren B., Orth K., Roberts JM, Ross R. ( 1998). Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: Role of a caspase cascade. Molecular Cell 1: 553—563.
  • Liu DF, Ferguson K., Cooper GS, Grady WM, Willis J. (1999). p27 cell-cycle inhibitor is inversely correlated with lymph node metastases in right-sided colon cancer. J Clin Lab Anal 13: 291—295.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Loda M., Cukor B., Tam SW, Lavin P., Fiorentino M., Draetta, GF, Jessup JM, Pagano M. (1997). Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Medicine 3: 231—234.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mahler JF, Flagler ND, Malarkey DE, Mann PC, Haseman JK, Eastin W. (1998). Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice. Toxicol Pathol 26: 501—511.[Abstract/Free Full Text]
  • Maron DM, Ames BN ( 1983). Revised methods for the Salmonella mutagenicity test. Mutat Res 113: 173—215.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Maronpot RR, Boorman GA (1996). The contribution ofthe mouse in hazard identification studies. Toxicol Pathol 24: 726—731.[Abstract/Free Full Text]
  • Masciullo V., Sgambato A., Pacilio C., Pucci B., Ferrandina G., Palazzo J., Carbone A., Cittadini A., Mancuso S., Scambia G., Giordano A. (1999). Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res 59: 3790—3794.[Abstract/Free Full Text]
  • Mori M., Mimori K., Shiraishi T., Tanaka S., Ueo H., Sugimachi K., Akiyoshi T. (1997). p27 expression and gastric carcinoma. Nature Medicine 3: 593.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nakayama K., Ishida N., Shirane M., Inomata A., Inoue T., Shishido N., Horii I., Loh D. (1996). Mice lacking p27 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85: 707—720.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • National Toxicology Program. 10th Report on Carcinogens. 10. 12-17-2002. <http://ehp.niehs.nih.gov/roc/toc10.html>, National Institute of Environmental Health Sciences. Ref Type: Report.
  • Newcomb EW, Sosnow M., Demopoulos RI, Zeleniuch-Jacquotte A., Sorich J., Speyer JL (1999). Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors. Am J Pathol 154: 119—125.[Abstract/Free Full Text]
  • Osawa H., Shitara Y., Shoji H., Mogi A., Kuwano H., Hagiwara K., Takenoshita S. (2000). Mutation analysis of transforming growth factor beta type II receptor, Smad2, Smad3 and Smad4 in esophageal squamous cell carcinoma. Int J Oncol 17: 723—728.[Web of Science][Medline] [Order article via Infotrieve]
  • Oshita F., Kameda Y., Nishio K., Tanaka G., Yamada K., Nomura I., Nakayama H., Noda K. ( 2000). Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer. Oncol Rep 7: 491—495.[Web of Science][Medline] [Order article via Infotrieve]
  • Palmqvist R., Stenling R., Oberg A., Landberg G. (1999). Prognostic significance of p27(Kip1) expression in colorectal cancer: A clinico-pathological characterization. J Pathol 188: 18—23.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Park MS, Rosai J., Nguyen HT, Capodieci P., Cordon-Cardo C., KoffA (1999). p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. Proc Natl Acad Sci USA 96: 6382—6387.[Abstract/Free Full Text]
  • Pettit SD (2001). Panel discussion on the application of alternative models to cancer risk assessment. Toxicol Pathol 29(Suppl): 191—195.[Abstract/Free Full Text]
  • Philipp J., Vo K., Gurley KE, Seidel K., Kemp CJ ( 1999). Tumor suppression by p27/Kip1 and p21/Cip1 during chemically induced skin carcinogenesis. Oncogene 18: 4689—4698.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Philipp-Staheli J., Kim KH, Payne SR, Gurley KE, Liggitt D., Longton G., Kemp CJ (2002). Pathway-specific tumor suppression. Reduction of p27 accelerates gastrointestinal tumorigenesis in Apc mutant mice, but not in Smad3 mutant mice. Cancer Cell 1: 355—368.
  • Philipp-Staheli J., Payne SR, Kemp CJ (2001). p27(Kip1): Regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res 264: 148—168.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Polyak K., Lee MH, Erdjument-Bromage H., Koff A., Roberts JM, Tempst P., Massague J. (1994). Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59— 66.
  • Popp JA (2001). Criteria for the evaluation of studies in transgenic models. Toxicol Pathol 29(Suppl): 20—23.[Abstract/Free Full Text]
  • Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM (1997). Expression of cell-cycle regulators p27 Kip-1 and cyclin E alone and in combination, correlate with survival in young breast cancer patients. Nature Medicine 3: 222—225.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Robinson DE, MacDonald JS (2001). Background andframeworkfor ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute. Toxicol Pathol 29(Suppl): 13—19.[Abstract/Free Full Text]
  • Saitoh A., Kimura M., Takahashi R-I., Yokoyama M., Nomura T., Izawa M., Sekiya T., Nishimura S., Katsuki M. (1990). Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene 5: 1195—1200.[Web of Science][Medline] [Order article via Infotrieve]
  • Sgambato A., Cittadini A., Faraglia B., Weinstein IB (2000). Multiple functions of p27(Kip1) and its alterations in tumor cells: A review. J Cell Physiol 183: 18—27.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sgambato A., Ratto C., Faraglia B., Merico M., Ardito R., Schinzari G., Romano G., Cittadini AR (1999). Reduced expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in human colon cancer. Mol Carcinog 26: 172—179.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Shamma A., Doki Y., Tsujinaka T., Shiozaki H., Inoue M., Yano M., Kawanishi K., Monden M. (2000). Loss ofp27(KIP1) expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Oncology 58: 152— 158.
  • Sherr CJ, Roberts JM (1995). Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9: 1149—1163.[Free Full Text]
  • Sherr CJ, Roberts JM (1999). CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 13: 1501—1512.[Free Full Text]
  • Singh SP, Lipman J., Goldman H., Ellis FH, Jr, Aizenman L., Cangi MG, Signoretti S., Chiaur DS, Pagano M., Loda M. ( 1998). Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 58: 1730—1735.[Abstract/Free Full Text]
  • Slingerland J., Pagano M. (2000). Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 183: 10—17.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Spalding JW, French JE, Tice RR, Furedi-Machacek M., Haseman JK, Tennant RW (1999). Development of a transgenic mouse model for carcinogenesis bioassays: Evaluation of chemically induced skin tumors in Tg.AC mice. Toxicol Sci 49: 241—254.[Abstract/Free Full Text]
  • Spalding JW, Momma J., Elwell MR, Tennant RW (1993). Chemically induced skin carcinogenesis in a transgenic mouse line (TG-AC) carrying a v-Ha-ras gene. Carcinogenesis 14: 1335—1341.[Abstract/Free Full Text]
  • Tamaoki N. (2001). The rasH2 transgenic mouse: Nature of the model and mechanistic studies on tumorigenesis. Toxicol Pathol 29(Suppl): 81—89.[Abstract/Free Full Text]
  • Tan P., Cady B., Wanner M., Worland P., Cukor B., Magi-Galluzzi C., Lavin P., Draetta G., Pagano M., Loda M. ( 1997). The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 57: 1259—1263.[Abstract/Free Full Text]
  • Teixeira LT, Kiyokawa H., Peng XD, Christov KT, Frohman LA, Kineman RD (2000). p27Kip1-deficient mice exhibit accelerated growth hormone-releasing hormone (GHRH)-induced somatotrope proliferation and adenoma formation. Oncogene 19: 1875—1884.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Tennant RW, Spalding J., French JE (1996). Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mutat Res 365: 119—127.[Web of Science][Medline] [Order article via Infotrieve]
  • Tennant RW, Stasiewicz S., Eastin WC, Mennear JH, Spalding JW (2001). The Tg.AC (v-Ha-ras) transgenic mouse: Nature of the model. Toxicol Pathol 29(Suppl): 51—59.[Abstract/Free Full Text]
  • Thomas GV, Szigeti K., Murphy M., Draetta G., Pagano M., Loda M. ( 1998). Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am J Pathol 153: 681—687.[Abstract/Free Full Text]
  • Thompson KL, Rosenzweig BA, Sistare FD (1998). An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. II. A genotypic marker that predicts tumorigenic responsiveness. Toxicol Pathol 26: 548—555.[Abstract/Free Full Text]
  • Trempus CS, Mahler JF, Ananthaswamy HN, Loughlin SM, French JE, Tennant RW (1998). Photocarcinogenesis and susceptibility to UV radiation in the v-Ha-ras transgenic Tg.AC mouse. J Invest Dermatol 111: 445— 451.
  • Tsihlias J., Kapusta LR, DeBoer G., Morava-Protzner I., Zbieranowski I., Bhattacharya N., Catzavelos GC, Klotz LH, Slingerland JM (1998). Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 58: 542—548.[Abstract/Free Full Text]
  • Tsihlias J., Kapusta L., Slingerland J. (1999). The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med 50: 401—423.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • van Steeg H., de Vries A., van Oostrom CT, van Benthem J., Beems RB, Van Kreijl CF (2001). DNA repair-deficient Xpa and Xpa/p53+/- knock-out mice: Nature of the models. Toxicol Pathol 29(Suppl): 109—116.[Abstract/Free Full Text]
  • Wang D., Kanuma T., Takama F., Mizumuma H., Ibuki Y., Wake N., Mogi A., Shitara Y., Hagiwara K., Takenoshita S. (1999). Mutation analysis of the Smad3 gene in human ovarian cancers. Int J Oncol 15: 949—953.[Web of Science][Medline] [Order article via Infotrieve]
  • Weaver JL, Contrera JF, Rosenzweig BA, Thompson KL, Faustino PJ, Strong JM, Ellison CD, Anderson LW, Prasanna HR, Long-Bradley PE, Lin KK, Zhang J., Sistare FD (1998). An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. I. Evidence for a confounding nonresponder phenotype. Toxicol Pathol 26: 532—540.[Abstract/Free Full Text]
  • Xiangming C., Natsugoe S., Takao S., Hokita S., Tanabe G., Baba M., Kuroshima K., Aikou T. (2000). The cooperative role of p27 with cyclin E in the prognosis of advanced gastric carcinoma. Cancer 89: 1214— 1219.
  • Yamamoto S., Urano K., Koizumi H., Wakana S., Hioki K., Mitsumori K., Kurokawa Y., Hayashi Y., Nomura T. (1998). Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. Environ Health Perspect 106(Suppl) 1: 57— 69.
  • Yang RM, Naitoh J., Murphy M., Wang HJ, Phillipson J., deKernion JB, Loda M., Reiter RE (1998). Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urology 159: 941— 945.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yasui W., Kudo Y., Semba S., Yokozaki H., Tahara E. (1997). Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res 88: 625—629.[CrossRef][Web of Science]
  • Yatabe Y., Masuda A., Koshikawa T., Nakamura S., Kuroishi T., Osada H., Takahashi T., Mitsudomi T. (1998). p27KIP1 in human lung cancers: Differential changes in small cell and non-small cell carcinomas. Cancer Res 58: 1042—1047.[Abstract/Free Full Text]
  • Zeiger E. (1987). Carcinogenicity of mutagens: Predictive capability of the Salmonella mutagenesis assay for rodent carcinogenicity. Cancer Res 47: 1287—1296.[Abstract/Free Full Text]
  • Zhu Y., Richardson JA, Parada LF, Graff JM (1998). Smad3 mutant mice develop metastatic colorectal cancer. Cell 94: 703—714.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Toxicologic Pathology, Vol. 31, No. 4, 355-363 (2003)
DOI: 10.1080/01926230390201273
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Payne, S. R.
Right arrow Articles by Kemp, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Payne, S. R.
Right arrow Articles by Kemp, C. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?